Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02909777 · ClinicalTrials.gov registry record · Phase 1
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT02909777 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 26 participants.
The verdict
NCT02909777, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.
Interventions
- DRUG CUDC-907
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-10 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02909777
The ClinicalTrials.gov registry entry for NCT02909777 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CUDC-907 is the first listed.
NCT02909777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02909777 about?
NCT02909777 is a clinical study titled "Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma". This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.
What is the current status of trial NCT02909777?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2016-10. Estimated completion is 2025-12.
What interventions are being tested in trial NCT02909777?
The interventions under investigation include: CUDC-907 (DRUG).
Who is sponsoring clinical trial NCT02909777?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.